Pillstats
Rx only · Capsule · Oral

Dabigatran Etexilate Mesylate

Brands: Pradaxa · Dabigatran Etexilate Mesylate

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US3 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)1037042
US makers1 labelers
Packages6
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 6 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.910$1.82$2.73$3.64Dec 2025Apr 2026Jul 2026
$3.162
Latest avg · Jul 22, 2026
-0%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

3.2K6.4K9.5K13K2025 Q12025 Q22025 Q32025 Q42026 Q1
2.7K
Rx · 2026 Q1
201K
Units dispensed
-76%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Boehringer Ingelheim Pharmaceuticals, Inc.unknown6SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.